A preprint reporting the patterns of failure after salavage Surgery and reRT for HNSCC. LRR occur within or near the reRT field. First recurrence site is a major predictor. Balancing optimal reRT volumes crucial for patient outcomes. Jack Phan MD PhD 𝖉𝖆𝖛𝖊 𝖋𝖚𝖑𝖑𝖊𝖗 @[email protected] Anna Lee
#ChemoShortages of #cisplatin and #carboplatin in #HNSCC would leave us with scant options. NO *Preferred* or *Other Recommended* drug options per National Comprehensive Cancer Network (NCCN) for CURABLE head/neck cancers 😬. U.S. FDA ASCO AHNS
Our second major paper in 2023. Remarkable how the same combination but in different setting (EBV-associated NPC) has a much better response compared to HNSCC despite being heavily pre-treated! rdcu.be/db92X Melvin LK CHUA Bruce Ashford Vin Paleri Ravi Uppaluri, MDPhD Umamaheswar Duvvuri MD PhD
Outcomes of 6 months post radiotherapy PET-CT for residual nodal disase in HPV related HNSCC presented by Claire Paterson #BAHNO2023 Claire Paterson 💙
Big day tomorrow.
BAHNO Head & Neck annual meeting 2023.
Two oral and two posters.
Radiological ENE in HNSCC, Crossectional imaging in thyroid cancer, NIRADS in HNSCC and sub-compartmentalisation of T4b in Oral HNSCC. #BAHNO2023 #HNSCC Head & Neck Cancer CEN (North) Head and Neck Cancer CA
Congratulations to MD Anderson-UTH Grad PhD student Gema Sunga for getting her first publication with the Young/Sikora labs, reviewing biomaterials-based methods to enhance immunotherapies in HNSCC! liebertpub.com/doi/abs/10.108…
Yesterday was a big! On behalf of the DAHANCA group, I had the great honor to present the results of our point of origin based pattern of failure study on IMRT treated patients with cancer of unknown primary in the head and neck (HNSCC CUP) at ESTRO
ESTRO Department of Oncology, Aarhus University Hospital
